Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550418 | 1.00 | CTSL (0.56) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL4823158 | 0.99 | CTSS (0.54) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL1143391 | 0.96 | CTSL (0.51) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL2535173 | 0.94 | SYK (0.49) | CTSLCTSSCTSBSYKCA12 | |
| SCHEMBL7352450 | 0.89 | CTSS (0.60) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL18482459 | 0.88 | SYK (0.45) | CTSLCTSSCTSBSYKCA12 | |
| SCHEMBL18482457 | 0.88 | SYK (0.45) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL1147367 | 0.86 | CTSL (0.43) | CTSLCTSSCTSBSYKKMT2A | |
| SCHEMBL28776844 | 0.85 | SYK (0.46) | CTSLCTSSCTSBSYKCA12 | |
| SCHEMBL5324101 | 0.85 | CTSS (0.61) | CTSLCTSSCTSBCTSKCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300287-A1 | Peptidic Compounds | VIP, NGLY1, FURIN | CTSL 115/4885CTSS 449/4885CTSB 248/4885 |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | CTSL 106/4885CTSS 103/4885CTSB 116/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | CTSL 66/4885CTSS 354/4885CTSB 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.